Hostname: page-component-586b7cd67f-l7hp2 Total loading time: 0 Render date: 2024-11-22T21:37:31.088Z Has data issue: false hasContentIssue false
  • English
  • Français

The Right Patients for the Drug: Managing the Placebo Effect in Antidepressant Trials

Published online by Cambridge University Press:  01 March 2007

Andrew Lakoff
Andrew Lakoff
Affiliation:
Department of Sociology, University of California, San Diego, 9500 Gilman Drive, 0533 La Jolla, CA 92093-0533, USA E-mail: [email protected]
Get access

Abstract

This article concerns the challenges faced by pharmaceutical researchers seeking to develop novel antidepressants. Based on ethnographic and documentary research into the drug development process, it shows how researchers try to manage the problem of the placebo response in antidepressant trials. The high rate of placebo response in these trials makes it difficult to demonstrate efficacy and often leads to trial failure. According to researchers, a major reason for high placebo response rates is the inability of standardized rating scales to define a coherent group of ‘drug responders’. They have developed alternative means of classifying patients in order to circumvent this problem and thereby improve the chances of trial success. In their search for ‘the right patients for the drug’, pharmaceutical researchers also provide an incisive critique of the epistemological assumptions underlying the clinical trial process.

Keywords

clinical trialsdrug developmentplacebo effectpsychiatry
Type
Articles
Information
BioSocieties , Volume 2 , Issue 1: Special Issue: The Construction and Governance of Randomised Controlled Trials , March 2007 , pp. 57 - 71
Copyright
Copyright © London School of Economics and Political Science 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bodewitz, H., Buurma, H., & de Vries, G.H. (1987). Regulatory science and the social management of trust in medicine. In Bijker, W.Hughes, T.& Pinch, T.(Eds), The social construction of technological systems: New directions in the sociology and history of technology. Cambridge, MA: MIT Press.Google Scholar
Ehrenberg, A. (1998). La Fatigue d’être soi. Paris: Odile Jacob.Google Scholar
Espeland, W.N., & Stevens, M.L. (1998). Commensuration as a social process. Annual Reviews in Sociology, 24, 313–43.Google Scholar
Faries, D.E., Heiligenstein, J.H., Tollefson, G.D., & Potter, W.Z. (2000). The double blind variable placebo lead-in period: Results from two antidepressant clinical trials. Journal of Clinical Psychopharmacology, 21, 561–8.Google Scholar
Geertz, C. (1983). Local knowledge: Further essays in interpretive anthropology. New York: Basic Books.Google Scholar
Goode, E. (2002). Antidepressants lift clouds, but lose ‘miracle drug label’. New York Times, 30 June.Google Scholar
Hamilton, M. (1960). A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry, 23, 56–62.Google Scholar
Hamilton, M. (1972). Rating scales in depression. In Krelholze, P. (Ed.), Depressive illness: Diagnosis, assessment, treatment. Baltimore, MD: Williams & Wilkins Co.Google Scholar
Harrington, A. (2002). ‘Seeing’ the placebo effect: Historical legacies and present opportunities. In Guess, H.A.Kleinman, A.Kusek, J.W. & Engel, L.W.(Eds), The science of the placebo: Toward an interdisciplinary research agenda. London: BMJ Books.Google Scholar
Healy, D. (1996a). The antidepressant era. Cambridge, MA: Harvard University Press.Google Scholar
Healy, D. (1996b). The psychopharmacologists. New York: Altman.Google Scholar
Kaptchuk, T.J. (1998). Intentional ignorance: A history of blind assessment and placebo controls in medicine. Bulletin of the History of Medicine, 72, 389–433.Google Scholar
Kleinman, A. (1988). Rethinking psychiatry: From cultural category to personal experience. New York: Free Press.Google Scholar
Kramer, M.S., Cutler, N., Feighner, J., Shrivastava, R., Carman, J., Sramek, J.J. et al. (1998). Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science, 281, 1640–1645.Google Scholar
Krishnan, K. (2000). Efficient trial designs to reduce placebo requirements. Biological Psychiatry, 47, 724–726.CrossRefGoogle ScholarPubMed
Lakoff, A. (2005). Pharmaceutical reason: Knowledge and value in global psychiatry. Cambridge: Cambridge University Press.Google Scholar
Langreth, R. (2002). Betting on the brain. Forbes, 7 January, 56–59.Google Scholar
Lasagna, L., Mosteller, F., von Felsinger, J.M., & Beecher, H.K. (1954). A study of the placebo response. American Journal of Medicine, 16, 770–779.Google Scholar
Leber, P. (2000). The use of placebo control groups in the assessment of psychiatric drugs: An historical context. Biological Psychiatry, 47, 699–706.CrossRefGoogle ScholarPubMed
Lévi-Strauss, C. (1963). The sorcerer and his magic. In Structural anthropology, trans. Jacobson, C.New York: Basic Books.Google Scholar
McNair, D.M., Gardos, G., Haskell, D.S., & Fisher, S. (1979). Placebo response, placebo effect, and two attributes. Psychopharmacology, 63, 245–350.CrossRefGoogle ScholarPubMed
Marks, H. (1997). The progress of experiment. Cambridge: Cambridge University Press.Google Scholar
Moerman, D. (1997). Physiology and symbols: The anthropological implications of the placebo effect. In Romanucci-Ross, L.Moerman, D.E.& Tancredi, L.R. (Eds), The anthropology of medicine: From culture to method, 2nd edn. Westport, CT: Bergin & Garvey.Google Scholar
Montgomery, S.A. (1999). The failure of placebo-controlled studies. European Neuropsychopharmacology, 9, 271–276.CrossRefGoogle ScholarPubMed
Nuland, S. (2001). The uncertain art: Mind, body, and the doctor. American Scholar, summer: 123–126.Google Scholar
Pignarre, P. (2001). Comment la dépression est devenue une épidémie? Paris: La Découverte.Google Scholar
Porter, T. (1995). Trust in numbers. Princeton, NJ: Princeton University Press.Google Scholar
Quitkin, F. (1999). Placebos, drug effects, and study design: A clinician's guide. American Journal of Psychiatry, 156, 829–836.Google Scholar
Quitkin, F.M., McGrath, P.J., Stewart, J.W., Ocepek-Welikson, K., Taylor, B.P., Nunes, E. et al. (1998). Placebo run-in period in studies of depressive disorders: Clinical, heuristic and research implications. British Journal of Psychiatry, 173, 242–248.Google Scholar
Quitkin, F.M., Rabkin, J.G., Gerald, J., David, J.M., & Klein, D.F. (2000). Validity of clinical trials of antidepressants. American Journal of Psychiatry, 157, 327–337.Google Scholar
Rosenberg, C. (1992). Explaining epidemics, and other studies in the history of medicine. Cambridge: Cambridge University Press.Google Scholar
Schatzberg, A.F., & Kraemer, H.C. (2000). Review of placebo control groups in evaluating efficacy of treatment of unipolar major depression. Biological Psychiatry, 47, 736–744.Google Scholar
Timmermans, S., & Berg, M. (1997). Standardization in action: Achieving local universality through medical protocols. Social Studies of Science, 27, 273–305.Google Scholar
Trivedi, M.H., & Rush, H. (1994). Does a placebo run-in or a placebo treatment cell affect the efficacy of antidepressant medications? Neuropsychopharmacology, 11, 33–43.CrossRefGoogle ScholarPubMed
Womack, T., Potthoff, J., & Udell, C. (2001). Placebo response in clinical trials. Applied Clinical Trials, February, 32–44.Google Scholar